Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients
Abstract Background BPaL, a 6 month oral regimen composed of bedaquiline, pretomanid, and linezolid for treating extensively drug-resistant tuberculosis (XDR-TB) is a potential alternative for at least 20 months of individualized treatment regimens (ITR). The ITR has low tolerability, treatment adhe...
Main Authors: | S. E. J. van de Berg, P. T. Pelzer, A. J. van der Land, E. Abdrakhmanova, A. Muhammad Ozi, M. Arias, S. Cook-Scalise, G. Dravniece, A. Gebhard, S. Juneja, R. Handayani, D. Kappel, M. Kimerling, I. Koppelaar, S. Malhotra, B. Myrzaliev, B. Nsa, J. Sugiharto, N. Engel, C. Mulder, S. van den Hof |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-07-01
|
Series: | BMC Public Health |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12889-021-11427-y |
Similar Items
-
A study on pre-XDR & XDR tuberculosis & their prevalent genotypes in clinical isolates of Mycobacterium tuberculosis in north India
by: Parul Singhal, et al.
Published: (2016-01-01) -
Prevalence of Pre-Extensively Drug-Resistant Tuberculosis (Pre XDR-TB) and Extensively Drug-Resistant Tuberculosis (XDR-TB) among Pulmonary Multidrug Resistant Tuberculosis (MDR-TB) at a Tertiary Care Center in Mumbai
by: Unnati D. Desai, et al.
Published: (2016-07-01) -
Comparison between the BACTEC MGIT 960 system and the agar proportion method for susceptibility testing of multidrug resistant tuberculosis strains in a high burden setting of South Africa
by: Said Halima M, et al.
Published: (2012-12-01) -
Turning the tide against tuberculosis
by: Nesri Padayatchi, et al.
Published: (2017-03-01) -
Drug-resistant tuberculosis: an experience from Qatar
by: Maisa Ali, et al.
Published: (2020-01-01)